Research programme: monoclonal antibodies - Aridis Pharmaceuticals
Alternative Names: Anti-infective mAbs - Kenta Biotech/Aridis; KBPA 102; KBPA 103; KBPA 104; KBSA 201; KBSA 302Latest Information Update: 28 Dec 2021
Price :
$50 *
At a glance
- Originator Kenta Biotech
- Developer Aridis Pharmaceuticals; Kenta Biotech
- Class Antibacterials; Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
- Discontinued Pseudomonal infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)
- 12 Mar 2018 Discontinued - Preclinical for Pseudomonal infections in Switzerland (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pseudomonal-infections in Switzerland (Parenteral)